Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Weighted Average): 2021-2025

Historic Shares Outstanding (Weighted Average) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $74.1 million.

  • Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) rose 4.02% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year increase of 4.02%. This contributed to the annual value of $72.2 million for FY2024, which is 2.65% up from last year.
  • Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) amounted to $74.1 million in Q3 2025, which was up 1.56% from $73.0 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) peaked at $74.1 million during Q3 2025, and registered a low of $68.2 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $70.9 million (2024), whereas its average is $71.4 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) decreased by 0.90% in 2023 and then grew by 4.02% in 2025.
  • Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) (MRQ) stood at $68.9 million in 2021, then grew by 0.93% to $69.5 million in 2022, then grew by 1.16% to $70.3 million in 2023, then grew by 2.65% to $72.2 million in 2024, then increased by 2.64% to $74.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $74.1 million for Q3 2025, versus $73.0 million for Q2 2025 and $72.6 million for Q1 2025.